you, results call. financial operator. quarter third XXXX Good Thank afternoon our and welcome to
our and CFO; Investor Kindred Joining Katja me Bio of COO; today Wendy our Bevers, Relations. team VP Wee, from our are President and and Buhrer, of the Denise Development management Corporate
release, As distributor revenue than we stated ordering the norm patterns, quarterly revenues in our quarter, that is note $X.X press third in which lower are while reflect should this industry. our the in ongoing the million in I expected. we was variability
the more from to continues and which Sales meaning strongly to reflects grew accurately for true that distributors customer important Mirataz demand is metric is an grow, clinics demand.
other to key As Denise metrics for will look Mirataz. continue outline, favorable
We Europe in CVMP. the globally. are the approval for largest the given from the Mirataz about positive opinion the for very veterinary EU, second market therapeutics upcoming is anticipated excited
active swifter, we veterinarians human and exceeded the may For uptake there's ingredient European an the if are generic with in its in same could drug sales believe Mirataz, usually the sales prohibited using be because EU US from veterinary approved
active with EU discussions to multiple in are Mirataz. about We partners rights
in for track approval on the this by be to Zimeta continue also end US We of month.
process process. in are manufacturing the we of scaling IL-XX, the up Regarding
this to than bit is during often the up know, we and process longer need you to a changes you As expected. make taking scale
may we changes the is lower push the the of those back of XXXX. study and found make, that potential goods as cost So that's enhancements that some well. The that pivotal exploring can initiation we good to we're timeline substantially in the for news have going
and for in IL-XX commercial strong. I negotiations the assets continues companies to multiple be are with antibody rights the should also interest note to active that in we
are and by Our atopic of not first because There market, could to and actual Banfield XXXX early SINK the each making rooms year. in read higher research, data out XXXX. to study veterinarians. and Also, dermatitis quarter parvoviruses treatment about well, by that be based this antibody our mean are study excellent least year. or infected parvoviruses progress other the parvoviruses dogs of also expect prophylactic than on that of that believe next dogs infected - the dogs continue prophylaxis We're coming we expect greater data, the prophylactic that along We number at that seen segments expose the with of on is are market. our dogs likely the Banfield on program emergency the number is two which and need are by include shelters, doesn't be dogs of to end that the XXX,XXX number approval there half treats are dogs infected. published Based market in
the about this need us unmet vaccines. had drug ask we've Now, medical versus investors the some for
minutes spend science. to going few like I'd So a through the
get are don't there puppies at receive many the They available times multiple have or and all, While to be for administered vaccines don't vaccine complete Parvo. the series.
are that market of puppies XX suggests fully out Our vaccinated. research X only
is block maternal antibody their no starts antibodies point, happens they're until vaccine. to maternal their the off levels while antibodies are slowly More with The there enough puppy still importantly, protective. But high what puppy level mothers. from lives protect parvoviruses, antibody is enough the protective at to that the not the longer that drop from
drop maternal work. will the until further wait to before vaccine have antibody You levels the
a vulnerability. of always there's window So
they're At that's why forced go for survive down success very floor. you catch the The surfaces to a and in biologics, they pet infectious. should with we less position put and some a a puppy dog across on every time the Also, down from when ground virus. the hardy can down you to multiple Parvo are virus parvoviruses on are store, even into put promising a taking With shelters, one the leadership facility. comes sector. If long
me as doing addition, in a what we of capacity. now a not examples. we the In IP been give of do detail we portfolio manufacturing initial have couple but we're Most building strong disclose, have biologics. Also, enviable let you very
molecule of have, example, antibody the We will half-life that for ways believe substantially. the modifying developed the of we increase
clinical effect have this goods. Obviously, on profound can profile of cost and a
by antibodies. example, problem a using if another And dog antibodies, methods use A. purification protein protein purified A many goods conventional can't solved can't using we you Unlike difficult of become something As cost canine have in antibodies untenable. called human be manufacturing
filed building methods, We conventional with have of go for I won't that portfolio. discovered on and a is technologies towards are created, are a standpoint of goods that these way our into which very but strong have IP on scientists from antibodies a purifying IP other we important way have technology. cost very we
capabilities. sources us of see intend runway capital. We that the manufacturing our key maturation announced the to facility great human spending XXXX and has NCI XXXX, other debt Turning expect which until to and judicious and recent drugs, will awarded the with our with pipeline. recently financial we supplement gives contract OpEx our launches we transform decrease this to to position, that convergence between The of of be XXXX. we our of company. a a cash to for anticipate and extend non-dilutive approvals financing validation continue We and multiple further us in our burn We potential is
on position partnering the our discussions I mentioned earlier, and extended are deep for progress on the We as in future. strongly also runway pipeline our are
the With over call Denise. to will that, turn I
